Introduction
Epigenetic modifications, including DNA methylation, govern gene expression.
Aberrant methylation by DNA methyltransferases can lead to tumorigenesis, so that efficient detection of methyltransferase activity provides an early cancer diagnostic.
Current methods, requiring fluorescence or radioactivity, are cumbersome; electrochemical platforms, in contrast, offer high portability, sensitivity, and ease of use.
We have developed a label-free electrochemical platform to detect the activity of the most abundant human methyltransferase, DNMT1, and have applied this method in detecting DNMT1 in crude lysates from both cultured human colorectal cancer cells (HCT116) and colorectal tissue samples.
DNA methylation powerfully influences gene expression in cells. 1, 2 DNA methyltransferases are responsible for maintaining a genomic pattern of methyl groups, which are covalently added to cytosine at predominantly 5ʹ-CG-3ʹ sites. Although essential for many cellular processes, aberrant methylation is associated with cancer. In particular, abnormal activity of DNA methyltransferases can lead to hypermethylation, which can silence tumor suppressor genes and promote cancerous transformations. [3] [4] [5] [6] The most abundant mammalian methyltransferase and an important diagnostic target is DNMT1, which preferentially methylates hemimethylated DNA using the cofactor Sadenosyl-L-methionine (SAM). [7] [8] [9] [10] Current measurements of DNMT1 activity require [methyl-3 H]-SAM to observe radioactive labeling of DNA, 8, 11 or expensive fluorescence or colorimetric reagents with antibodies that require large instrumentation, 12, 13 both of which are significant obstacles that impede more widespread assessment of DNMT1 activity.
Traditionally, electrochemistry has been used to overcome such limitations for biomolecule detection, as electrochemical methods are low cost, portable, and require only modest instrumentation. 14, 15 However, electrochemical detection schemes have typically been restricted to measurements of highly purified samples because of the increased congestion and decreased accessibility of surface (vs. solution) platforms.
Electrochemistry has been used to detect nucleic acids with high sensitivity and without the need for PCR amplification in bacterial lysate and serum, [16] [17] [18] [19] [20] but protein detection remains a challenge. 2, [21] [22] [23] In fact, although protein detection from simple serum has been accomplished, 24, 25 to date, no reported electrochemical systems have effectively detected active protein of any kind from crude cell lysate.
We have recently developed a unique electrochemical detection architecture aimed at overcoming the challenges associated with protein detection from complex biological samples. This multiplexed detection system involves a substrate plate consisting of a 15-electrode array and a complementary patterning and detection plate also containing a 15-electrode array, which combines low-density DNA monolayer patterning with the electrocatalytically amplified measurement of DNA charge transport (DNA CT) chemistry at a secondary electrode. 26 The low-density DNA monolayer enables protein access to the DNA even in highly congested lysate samples, while electrocatalytic signal amplification markedly increases sensitivity.
We utilize measurements of DNA CT through the DNA helices in the monolayer because of the high sensitivity of this chemistry to perturbations in base stacking caused by mismatches, lesions, and protein binding. 27, 28 Methylene blue, a freely diffusing redox-active probe that is activated by DNA CT, interacts with the DNA stack and thereby reports on the integrity of DNA CT through the monolayer. We use direct detection from the secondary electrode of the turnover of the electrocatalytic partner to methylene blue, ferricyanide, as 
Materials and Methods

DNA Synthesis and Purification
Oligonucleotides were either synthesized on an Applied Biosystems 3400 DNA synthesizer or purchased from IDT. The terminal C6 alkyne moiety that was incorporated into the 5ʹ end of one of the strands was purchased from Glen Research. Complementary unmodified strands were purchased from IDT. DNA was deprotected and cleaved from solid support with ammonium hydroxide (60° C for 12 h). Following a preliminary round of HPLC, oligonucleotides were treated with 80% acetic acid in water for 20 minutes. Each oligonucleotide was purified by high-performance liquid chromatography (HPLC) using a gradient of acetonitrile and 50 mM ammonium acetate. Following purification, oligonucleotides were desalted by ethanol precipitation and quantified by ultraviolet-visible spectrophotometry based on their extinction coefficients at 260 nm (IDT Oligo Analyzer). Oligonucleotide masses were verified by matrix-assisted laser desorption (MALDI) mass spectrometry. DNA duplexes were formed by thermally annealing equimolar amounts of single-stranded oligonucleotides in deoxygenated phosphate buffer (5 mM phosphate, 50 mM NaCl, pH 7.0) at 90 °C for 5 minutes followed by slowly cooling to 25 °C.
The following sequences were prepared:
The BssHII restriction site is shown in red.
Western Blot Analysis of Lysate for DNMT1
DNMT1 expression was confirmed by Western blot. Samples were mixed with Laemmli reagent and betamercaptoethanol and probe sonicated for 10 seconds, followed by heat inactivation at 90 °C for 5 minutes. Samples were loaded onto 4-12% polyacrylamide gels in MOPS buffer and run at 175 mV for 1.5 hours. Gels were subsequently transferred to membranes with a dry transfer procedure for 1.5 h. Membranes were then blocked with 5% milk in TBST at room temperature for 1 hour, followed by overnight 
H-SAM Methyltransferase Activity Assay
Methyltransferase activity was additionally tested using the conventional method of a 3 H-SAM incorporation activity assay. The activity assay followed a published protocol. 8, 11 Briefly, 20 µL total reaction volumes were used for the 3 
DNA Monolayer Formation
The two-electrode array was constructed as previously reported. 26 The A BCA assay (Pierce) was used to quantify the total amount of protein in the lysate. The total protein concentration at which the lysate was frozen was 3,500-5,000 µg/mL.
Tissue samples were obtained from CureLine. Colorectal carcinoma as well as healthy adjacent tissues were obtained. Approximately 150 mg of tissue were homogenized manually, followed by nuclear extraction, buffer exchange, storage, and quantification, as described above. The total protein concentration at which the lysate was frozen was 35,000-50,000 µg/mL.
Electrochemistry
All electrochemistry was performed on a bipotentiostat (BASinc.) with two working electrodes, a platinum wire counter electrode, and an AgCl/Ag reference electrode. Constant potential amperometry was performed for 90 seconds with an applied potential of 320 mV to the secondary electrode and -400 mV to the primary electrode relative to an AgCl/Ag reference electrode with a platinum counter electrode.
All scans were performed in Tris buffer (10 mM Tris, 100 mM KCl, 2.5 mM MgCl 2 , 1 mM CaCl 2 , pH 7.6) with 4 µM methylene blue and 300 µM potassium ferricyanide.
Scans were taken at each of the 15 secondary pin electrodes, and the reported variation in the data represents the standard error across three measurements of three electrodes, all at a given condition.
To incubate electrodes with desired proteins, a 1. 
Results and Discussion
Electrochemical Platform
Using a 15-pin setup, low-density DNA monolayers were formed on one set of electrode surfaces by DNA patterning from a secondary electrode. DNA substrates were optimized for length to balance on/off signal differential with the ability of proteins to access the binding site. For monolayer formation, thiol monolayers with 50% azide and 50% phosphate head groups first were prepared on the gold pins. We have previously characterized such low-density monolayers, and have found the total DNA coverage to be 20 pmol/cm 2 . 31 Subsequently, specific DNA sequences were tethered to individual pins using electrochemically-activated Cu 1+ click chemistry. 26 The secondary electrode activates the inert copper catalyst precursor only at specific locations on the primary electrode surface. Multiple sequences of DNA with different methylation states in the restriction enzyme binding site (either hemimethylated or unmethylated) were therefore patterned onto particular electrodes (Figure 4 In blue is the preliminary scan after an electrode modified with hemimethylated DNA has been treated with parent lysate, followed by treatment with 1 µM protease in phosphate buffer, both at 37° C. In red is the scan after the electrode was treated with 1500 units/mL BssHII for 1.5 h at 37° C. On the left is the final scan from an electrode with 160 µM SAM added to the lysate; the signals essentially overlay, indicating an 'on' signal. On the right is the final scan from an electrode without SAM added to the lysate; this produces an 'off' signal. The constant potential amperometry was run for 90 seconds with an applied potential of 320 mV to the secondary electrode and -400 mV to the primary electrode. All scans were performed in Tris buffer (10 mM Tris, 100 mM KCl, 2.5 mM MgCl 2 , 1 mM CaCl 2 , pH 7.6) with 4 µM methylene blue and 300 µM potassium ferricyanide. Bottom: Reproducibility within the two-electrode multiplexed array. Orientation of the tested conditions on the 5x3 array is shown (inset) with circular electrodes colored to correspond with activity data represented in the bar graph. Both the electrodes treated with 65 nM purified DNMT1 on hemimethylated DNA with 160 µM SAM (green) and those treated with parent (WT) lysate in the presence of SAM (solid blue) show full signal protection. On electrodes without added SAM (blue striped and red striped) and on DNMT1 -/lysate-treated electrodes in the presence of SAM (solid red), no signal protection is observed. Bar graph data are raw without standardization and error bars represent the standard deviation over three measurements.
Figure 4.6
Signal protection from differing amounts of lysate. All electrodes on this array were modified with hemimethylated DNA, and values are normalized to 100% protection of the DNMT1 electrodes. All samples include 160 µM SAM. The darkest blue is lysate from approximately 40,000 cells. The subsequent points are from 4,000 cells, 800 cells, and 400 cells. Full protection is afforded from approximately 4,000 cells. The constant potential amperometry was performed for 90 seconds with an applied potential of 320 mV to the secondary electrode and -400 mV to the primary electrode relative to an AgCl/Ag reference electrode with a platinum counter electrode. All scans were performed in Tris buffer (10 mM Tris, 100 mM KCl, 2.5 mM MgCl 2 , 1 mM CaCl 2 , pH 7.6) with 4 µM methylene blue and 300 µM potassium ferricyanide. Error bars represent the standard error for three electrodes over three measurements. 
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To further combat signal decreases caused by undesired DNA-binding proteins, after electrodes are treated with lysate, a protease treatment step is incorporated to remove remaining bound protein before the electrochemical measurements. This protease step further ensures that there is no remaining protein bound either to the DNA or directly to the surface that could interfere with electrochemical measurements.
Methyltransferase activity is then determined by the percent signal remaining after BssHII treatment. If the DNA is cut by the restriction enzyme, the signal is low, indicating little methyltransferase activity. It is noteworthy that the percent signal remaining is always non-zero because, even after restriction, a DNA fragment remains that can generate an electrochemical response with the noncovalent methylene blue redox probe; electrochemical amplification is proportional to the amount of bound methylene blue, and therefore to DNA length.
Differential Detection of DNMT1 Activity from Multiple Crude Cultured Cell Lysates
We then tested the ability of the platform to differentiate between lysate from a parent (HCT116 wild type) colorectal carcinoma cell line and a cell line that does not express DNMT1 (HCT116 DNMT1 -/-). As shown in Figure 4 
Detection of DNMT1 Activity from Human Tumor Tissue
Human biopsy tissue samples were similarly evaluated, and tumor tissue was readily distinguished from adjacent normal tissue (Figure 4.7) . Tissue biopsy samples were purchased from a commercial source and were thus handled and stored using conventional methods (snap freezing in liquid nitrogen after removal and storage at -80°
C for upwards of one month). The optimal amount of tissue for detection from these samples was found to be ~500 µg per electrode; typical colon punch biopsies yield 350 mg of tissue. 32 Samples of colorectal carcinoma tissue as well as the adjacent healthy tissue were prepared just as the cultured cell lysate was, and showed differential activity with our electrochemical platform. The tumor sample, which showed greater signal protection, was sensitive both to substrate and to cofactor, consistent with high DNMT1 methyltransferase activity, and similar to the cultured parent colorectal carcinoma cells.
In contrast, the normal tissue sample showed low methyltransferase activity, as seen through the reduced electrochemical signal (Figure 4.7) . These data clearly indicate that tumors can be effectively differentiated from healthy tissue through electrochemical DNMT1 measurement with our platform. By western blot, the relative abundance of DNMT1 in the tumor tissue as compared to healthy tissue was quantitatively consistent with the electrochemical results (Figure 4.2) .
Lysate activities were also tested by a 3 H-SAM assay, and relative activities of the various samples were comparable to those determined electrochemically (Figure 4.3) .
However, as is typical for such radioactivity assays, activity measurements observed among trials of the 3 H-SAM assay were extremely variable, much more so than with the electrochemical platform. Activity differences between the tumor and healthy tissue were seen only at concentrations of ~1 mg of tissue per sample, significantly higher than what is needed for electrochemical detection. The time required to obtain the data was additionally substantially longer.
Implications
DNMT1 is an important clinical diagnostic target due to its connection to aberrant genomic methylation, which is linked to tumorigenesis. Direct detection of methyltransferase activity from crude tissue lysates provides an early method of cancer screening and can also inform treatment decisions. However, current approaches for the detection of methyltransferase activity rely on radioactive or fluorescent labels, antibodies, and obtrusive instrumentation, which limit their application in laboratories and clinics. Although electrochemical approaches generally overcome these limitations, direct detection of proteins from crude samples remains challenging because of the complexity of crude biological lysates, as well as the sensitivity required to analyze the limited material of small clinical biopsy samples.
Our electrochemical assay for DNMT1 methylation effectively circumvents these problems. Methylation is detected through the presence or absence of DNA surface restriction followed by electrocatalytic amplification. We avoid clogging the platform through the formation of low-density DNA monolayers, enabling target DNA-binding proteins in the lysate ample access to the individual DNA helices on the surface. Our platform is also sensitive and selective without the use of radioactivity, fluorescence, or antibodies through the combination of electrocatalytic signal amplification and the sensitivity of DNA CT chemistry to report changes to the integrity of the DNA. This allows for detection of DNMT1 from both cultured colorectal carcinoma cells and tissue biopsy specimens. No difficult or time-consuming purification steps are necessary, and, for each electrode, only ~4000 cultured cells or ~500 µg tissue sample are required.
Importantly, because of the multiplexed nature of this platform, we are able to assay for substrate specificity while simultaneously measuring normal tissue and tumor tissue lysates. Therefore, with our platform, healthy tissue is easily distinguished from tumor tissue using very small amounts of sample. More generally, this work represents an important step in new electrochemical biosensing technologies.
